MicuRx to Present Findings at 7th World Bronchiectasis Conference

SHANGHAI, June 19, 2024 – Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH), a biopharmaceutical firm dedicated to developing innovative anti-infective therapies for severe infections, has announced its participation in the 7th World Bronchiectasis Conference. The event will be held from July 4 - 6, 2024, in Dundee, Scotland.

MicuRx will present findings from three new studies that shed light on two of its promising investigational candidates, MRX-5 and MRX-8. These presentations will highlight the nonclinical data supporting the potential of these therapies.

MRX-5 is an oral investigational drug aimed at treating adults suffering from nontuberculous mycobacteria (NTM) pulmonary diseases. This candidate has shown potent antimicrobial activity against Mycobacterium avium complex (MAC), the most prevalent NTM pathogen, and Mycobacterium abscessus complex (MABC), known for being more challenging to treat. MRX-5 is currently undergoing Phase 1 clinical trials, with topline results anticipated by the end of the third quarter of 2024.

MRX-8, a novel agent within the polymyxin class, is developed for nebulized administration to treat chronic Pseudomonas aeruginosa lung infections in patients with bronchiectasis. This includes infections caused by drug-resistant strains.

The presentations at the conference will cover the following topics:

1. "In Vitro And In Vivo Activity Of A Novel Leucyl-Trna Synthetase Inhibitor Against Mycobacterium Abscessus" – presented by Regis Vilchez, MD, PhD from MicuRx.
2. "In Vitro Activity of Novel Leucyl-tRNA Synthetase Inhibitor Against Mycobacterium Avium Complex" – presented by Wen Wang, PhD from MicuRx.
3. "In Vitro And In Vivo Activity Of A Novel Antibiotic In The Polymyxin Class Against Pseudomonas Aeruginosa" – presented by Wen Wang, PhD from MicuRx.

MicuRx, established in 2007, is committed to addressing the growing problem of global antimicrobial resistance. The company prides itself on its dedication to the discovery, development, and commercialization of innovative drugs to meet unmet medical needs. Guided by the principle "Better therapy through superior medicine," MicuRx continues to develop new solutions for infectious diseases with significant unmet needs.